Skip to main content

Table 1 Baseline demographic and clinical characteristics of the patients a

From: Hypophosphatemia during continuous veno-venous hemofiltration is associated with mortality in critically ill patients with acute kidney injury

Characteristics Patients
(N= 760)
Survivors
(n= 387)
Nonsurvivors
(n= 373)
P
Mean age (yr) 59.72 58.25 61.25 0.020
Male sex (%) 498 (65.5) 250 (64.6) 248 (66.5) 0.594
Premorbidity (%) 496 (65.3) 234 (60.5) 262 (70.2) 0.007
 Cardiovascular disease 171 78 93  
 Liver disease 94 37 57  
 Pulmonary disease 31 15 16  
 Cancer 77 34 43  
 Renal disease 63 41 22  
 Hematological disease 28 10 18  
Other 32 19 13  
Recent surgery (%) 272 (35.8) 138 (35.7) 134 (35.9) >0.999
Sepsis (%) 406 (53.4) 188 (48.6) 218 (58.4) 0.010
Main source of infection (%)     
 Chest 233 (57.3) 97 (51.6) 136 (62.4)  
 Abdomen 118 (29.1) 62 (33.0) 56 (25.7)  
 Bloodstream, including line-related infection 36 (8.9) 20 (10.6) 16 (7.3)  
Other or unknown source 19 (4.7) 9 (4.8) 10 (4.6)  
APACHE II score (mean) 21.04 19.42 22.72 <0.001
Mean length of mechanical ventilation (days) 8.01 8.30 7.70 0.290
Prescribed dose of CVVH (mean in first 72 hours, ml/kg/h) 48.53 47.67 49.42 0.089
Delivered dose of CVVH (median in first 72 hours, ml/kg/h) 41.00 40.32 41.71 0.542
Therapeutic time of CVVH (days) 7.94 8.20 7.67 0.271
Phosphate supplementation (%) 471 (62.0) 248 (64.1) 223 (59.8) 0.232
Hypophosphatemia during CVVH (%) 521 (68.6) 260 (67.2) 261 (70.0) 0.435
Severe hypophosphatemia (%) 109 (14.3) 44 (11.4) 65 (17.4) 0.022
  1. aAPACHE II, Acute Physiology Chronic Health Evaluation II; CVVH, continuous veno-venous hemofiltration. P-value represents live cohort vs. dead cohort.